EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models

Shaquia L. Idlett-Ali, Alexander T.H. Nguyen, Khalid N.M. Abdelazeem, Diemmy Nguyen, Nicholas A. Olimpo, Michael Knitz, Jacob Gadwa, Tyler Weiskpof, Chloe Hodgson, Harshita Kumar, David Ceja Galindo, Teddi Gray und 6 weitere

Journal of Clinical Investigation · 19.11.2026

DOI: 10.1172/jci204965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 19.11.2026. Verfasst von Shaquia L. Idlett-Ali und 17 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Society of Immunotherapy of Cancer, Sloan Scholars, US National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurogenic inflammation is one component that sculpts the immune milieu of solid tumors. However, it remains unclear how the sensory-neuroimmune axis shapes the immune microenvironment in cold tumors to bolster treatment resistance. Using orthotopic head and neck squamous cell carcinoma (HNSCC) models, we demonstrate tumor growth-induced sensory hyperexcitability, and that surgical sensory signaling interruption reduced tumor growth. Genetic knockout of a key neuropeptide released by sensory neurons, calcitonin gene-related peptide (CGRP), encoded by Calca , produced eradication when paired with radioimmunotherapy. Such treatment reduced Treg infiltration and immunosuppressive function in Calca knockout mice. We also observed that high-dose psilocybin functions as a CGRP inhibitor and transiently reduces tumor growth by increasing antitumor immunity. Additionally, psilocybin increased circulating serotonin, which was partially reversed with platelet activation inhibitor, clopidogrel. We observed differential effects on CD8 and Treg functionality by psilocin in vitro. Correlational analyses in plasma from human subjects following a single-dose psilocybin corroborated these findings. Together, this work underscores the complex interaction of neurogenic inflammation and the tumor immune microenvironment, highlighting a potential therapeutic avenue for HNSCC and other solid tumors.

Förderung

  • Society of Immunotherapy of Cancer
  • Sloan Scholars
  • US National Institutes of Health
  • Anschutz Medical Campus, University of Colorado
  • American Society for Radiation Oncology
  • National Institute of Dental and Craniofacial Research

Zitieren

APA

Idlett-Ali, S. L., Nguyen, A. T., Abdelazeem, K. N., Nguyen, D., Olimpo, N. A., Knitz, M., Gadwa, J., Weiskpof, T., Hodgson, C., Kumar, H., Galindo, D. C., Gray, T., Puram, S. V., Miller, D. L., Nicol, G. E., Saviola, A. J., Osborne, D. G., & Karam, S. D. (2026). Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci204965

Vancouver

Idlett-Ali SL, Nguyen AT, Abdelazeem KN, Nguyen D, Olimpo NA, Knitz M, et al. Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci204965

BibTeX
@article{IdlettAli2026,
  author = {Idlett-Ali, Shaquia L. and Nguyen, Alexander T.H. and Abdelazeem, Khalid N.M. and Nguyen, Diemmy and Olimpo, Nicholas A. and Knitz, Michael and Gadwa, Jacob and Weiskpof, Tyler and Hodgson, Chloe and Kumar, Harshita and Galindo, David Ceja and Gray, Teddi and Puram, Sidharth V. and Miller, Daniel L. and Nicol, Ginger E. and Saviola, Anthony J. and Osborne, Douglas G. and Karam, Sana D.},
  title = {Targeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci204965}
}
Kostenlos starten →